The History of Adrenocortical Carcinoma Treatment – A Surgical Perspective

  • Norman W. ThompsonEmail author


The early history of adrenocortical carcinoma (ACC) is obscure because of the rarity of the disease, confusing nomenclature, inability to diagnose before death, ignorance of its hormonal manifestations, and a vague appreciation of its clinical course. Most reported cases in the 19th century were based on autopsy findings, and the tumors were classified by a variety of terms including hypernephroma, sarcoma, fibromyxosarcoma, and carcinoma. The commonly used term, hypernephroma, was first proposed by Grawitz et al. in 1893 and falsely assumed that tumors arose in rests of adrenocortical tissue within the kidney [1]. This concept was reinforced by Felix Birch-Hirchfield who used it to define benign and malignant tumors of both adrenals and kidneys, some with apparent hormonal disturbances [2]. The designation of hypernephroma for some adrenal tumors persisted in the literature until the 1940s; later it became restricted to what is now referred to as renal cell cancer [3–8].


Adrenal Insufficiency Adrenal Tumor Local Invasion Adrenocortical Carcinoma Adrenal Adenoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Grawitz P (1883) Die sogenannten lipome der niere. Virchow’s Archiv Pathol Anal and Klin Med xciii:121–124Google Scholar
  2. 2.
    Rolleston HD (1936) The endocrine organs in health and disease. Oxford University Press, London, pp 301–384Google Scholar
  3. 3.
    Curtis BF (1900) Nephrectomy for suprarenal tumor. Ann Surg 31:759–760Google Scholar
  4. 4.
    Fey B (1926) L’abord du rein par voie thoraco-abdominal. Arch Urol Clin Necker 5:168–178Google Scholar
  5. 5.
    Holmes G (1925) Virilism associated with a suprarenal tumor. Q J Med 18:143–152Google Scholar
  6. 6.
    Kennedy CM, Lister WA (1927) Suprarenal hypernephroma. Lancet 2:739–751Google Scholar
  7. 7.
    Keyser LD, Walters W (1924) Carcinoma of the suprarenal. JAMA 82:87–88Google Scholar
  8. 8.
    Lisser H (1933) Successful removal of adrenal cortical tumor. Trans Associa Am Physicians 48:224–235Google Scholar
  9. 9.
    Richards O (1905) Growths of the kidneys and adrenals. Guy’s Hosp Rep 59:217–332Google Scholar
  10. 10.
    Welbourn RB (1990) The history of endocrine surgery. Praeger, New YorkGoogle Scholar
  11. 11.
    Walters W et al (1934) The suprarenal cortical syndrome. Ann Surg 100:670–688CrossRefPubMedGoogle Scholar
  12. 12.
    Thornton JK (1890) Abdominal nephrectomy for large sarcoma of the left suprarenal capsule: recovery. Trans Clin Soc London 23:150–153Google Scholar
  13. 13.
    Robson AWM (1899) Removal of the suprarenal capsule. Br Med J 2:1100–1101Google Scholar
  14. 14.
    Ramsay O (1899) Malignant tumors of the suprarenal gland. Johns Hopkins Hosp Bull nos 94–96:20–29Google Scholar
  15. 15.
    Walters W, Sprague RG (1949) Hyperfunctioning tumors of the adrenal cortex. Ann Surg 129:677–701Google Scholar
  16. 16.
    Broster LB et al (1932) Adreno-genital syndrome: unilateral adrenalectomy. Brit J Surg 19:557–570CrossRefGoogle Scholar
  17. 17.
    Kepler EJ, Keating FR (1941) Diseases of the adrenal glands. Arch Int Med 68:1010–1036Google Scholar
  18. 18.
    Murray GG, Simpson G (1929) Virilism due to an adrenal hypernephroma. Lancet 2:734–749Google Scholar
  19. 19.
    Rapaport E et al (1952) Mortality in surgically treated adrenocortical tumors. Postgrad Med 11:325–329PubMedGoogle Scholar
  20. 20.
    Thompson KW, Eisenharatt L (1943) Further consideration of the Cushing’s syndrome. J Clin Endocrinol Metab 3:445–452CrossRefGoogle Scholar
  21. 21.
    MacFarlane DA (1958) Cancer of the adrenal cortex. Ann R Coll Surg Engl 23:155–162PubMedGoogle Scholar
  22. 22.
    Priestly JT (1952) Lesions of the adrenal glands. Surg Clin N Am 32:1053–1064Google Scholar
  23. 23.
    Anderson HB (1933) Successful removal of adrenal cortical tumor. Trans Associa Am Physicians 48:224–235Google Scholar
  24. 24.
    Thompson NW (1983) Adrenocortical carcinoma.In: Thompson NW, Vinik AI (eds) Endocrine surgery update. Grune and Straton, New YorkGoogle Scholar
  25. 25.
    Sahteingart DE et al (1982) Treatment of adrenal carcinomas. Arch Surg 117:1142–1147Google Scholar
  26. 26.
    Cohn K et al (1986) Adrenocortical carcinoma. Surgery 100:1170–1177PubMedGoogle Scholar
  27. 27.
    Icard P et al (1992) Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 112:972–980PubMedGoogle Scholar
  28. 28.
    Kelly WF et al (1979) Cushing’s syndrome due to adrenocortical carcinoma. Acta Endocrinologica 91:303–318PubMedGoogle Scholar
  29. 29.
    Lewinsky BS et al (1974) The clinical and pathologic features of “non-hormonal” adrenocortical tumors. Cancer 33:778–790CrossRefPubMedGoogle Scholar
  30. 30.
    Lipsett MB et al (1963) Clinical and pathophysiologic aspects of adrenocortical carcinoma. Am J Med 35:374–383CrossRefPubMedGoogle Scholar
  31. 31.
    Richie JP, Gittes RE (1980) Carcinoma of the adrenal cortex. Cancer 45:1957–1964PubMedGoogle Scholar
  32. 32.
    Bergenstall DM et al (1960) Chemotherapy of ACC with o,pʹ-DDD. Ann Int Med 53:672–680Google Scholar
  33. 33.
    Hutter AM, Kayhoe DE (1966) Adrenal cortical carcinoma: clinical features of 138 patients. Am J Med 41:572–580CrossRefPubMedGoogle Scholar
  34. 34.
    Hutter MM, Jr, Kayhoe DE (1966) Adrenal cortical carcinoma. Results of treatment with o,pʹ-DDD in 138 patients. Am J Med 41:581–589CrossRefPubMedGoogle Scholar
  35. 35.
    Lubitz JA et al (1973) Mitotane use in inoperable adrenal cortical carcinoma. JAMA 223:1109–1112CrossRefPubMedGoogle Scholar
  36. 36.
    VanSlooten H et al (1984) The treatment of adrenocortical carcinoma with o,pʹ-DDD: prognostic simplification of serum level monitoring. Eur J Cancer Oncol 20:47–53CrossRefGoogle Scholar
  37. 37.
    Hogan TF et al (1978) o,pʹ-DDD (mitotane) therapy of adrenal cortical carcinoma. Cancer 42:2177–2188CrossRefPubMedGoogle Scholar
  38. 38.
    Lutton JP et al (1990) Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322:1195–1201CrossRefGoogle Scholar
  39. 39.
    Boven E et al (1984) Complete response of metastasized adrenal cortical carcinoma with o, pʹ-DDD. Cancer 53:26–29CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Surgery Emeritus FacultyUniversity of MichiganAnn ArborUSA

Personalised recommendations